AR054269A1 - Derivados de 2-amido-6-amino-8-oxopurina - Google Patents
Derivados de 2-amido-6-amino-8-oxopurinaInfo
- Publication number
- AR054269A1 AR054269A1 AR20060101788A ARP060101788A AR054269A1 AR 054269 A1 AR054269 A1 AR 054269A1 AR 20060101788 A AR20060101788 A AR 20060101788A AR P060101788 A ARP060101788 A AR P060101788A AR 054269 A1 AR054269 A1 AR 054269A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycle
- cycloalkyl
- phenyl
- naphthyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Más en particular, la presente se refiere al uso de derivados de purina en el tratamiento de diversas infecciones víricas y de trastornos inmunologicos o inflamatorios, entre ellos aquellos en los cuales se encuentra implicada la modulacion, y en particular el agonismo, de receptores similares al receptor Toll (siglas inglesas TLR). En consecuencia, los compuestos de la presente son utiles en el tratamiento de enfermedades infecciosas tales como hepatitis (por ejemplo las HCV, HBV), infecciones víricas relacionadas genéticamente, enfermedades inflamatorias tales como el asma y la artritis, y el cáncer. Reivindicacion 1: Un compuesto de formula (1) un tautomero del mismo, o una sal, solvato o polimorfo, farmacéuticamente aceptable, de dicho compuesto o tautomero, en la cual: R1 y R2 son cada uno, de manera independiente, H, alquilo C1-6, cicloalquilo C3-7, alquilo C1-6 sustituido con 1 a 3 cicloalquilo C3-7, un fenilo, naftilo o un heterociclo; cicloalquilo C3-7 sustituido con alquilo C1-6; S(O)nR8, o heterociclo, o bien R1 y R2, considerados junto con el átomo de N al cual están unidos, forman un heterociclo; estando en cada caso dichos alquilo, cicloalquilo, fenilo, naftilo y heterociclo sustituidos opcionalmente con 1 a 3 átomos o grupos seleccionados de oxo, halogeno, CF3, CN, R4, OR4, NR4R5, COR4, CO2R4, S(O)nR4, S(O)nR4R5, CONR4R5 y NR4COR5; R3 es alquilo C1-6, cicloalquilo C3-7, fenilo, naftilo, o heterociclo, estando dichos alquilo, cicloalquilo, fenilo, naftilo y heterociclo sustituidos opcionalmente con 1 a 3 átomos o grupos seleccionados de oxo, halogeno, CF3, CN, R4, OR4, NR4R5, COR4, CO2R4, S(O)nR4, S(O)nR4R5, CONR4R5 y NR4COR5; R4 y R5 son cada uno, de manera independiente, H, alquilo C1-6, cicloalquilo C3-7, alquenilo C2-6 o alquinilo C2-6, o bien R4 y R5, cuando están unidos al mismo átomo de N, forman un heterociclo, estando dichos alquilo, cicloalquilo y heterociclo sustituidos opcionalmente con 1 a 3 átomos o grupos seleccionados de fenilo, OR6, NR6R7, S(O)nR6, S(O)nR6R7 y NR6COR7; R6 y R7 son, de manera independiente, H, alquilo C1-6, o alquilo C1-6 sustituido con cicloalquilo C3-7, o bien R6 y R7, cuando están unidos al mismo átomo de N, forman un heterociclo; R8 es H, alquilo C1-6, cicloalquilo C3-7, fenilo, naftilo, o heterociclo, estando dichos alquilo, cicloalquilo, fenilo, naftilo y heterociclo sustituidos opcionalmente con 1 a 3 átomos o grupos seleccionados de oxo, halogeno, CF3, CN, fenilo, R4, OR4, NR4R5, COR4, CO2R4, S(O)nR4, S(O)nR4R5, CONR4R5 y NR4COR5; R9 es R10, COR10, CO2R10 o CONR10R11, y R9a está ausente, o bien R9a es R10, COR10, CO2R10, o CONR10R11, y R9 está ausente; R10 y R11 son cada uno, de manera independiente, H, alquilo C1-6, cicloalquilo C3-7, alquilo C1-6 sustituido con 1 a 3 cicloalquilos C3-7, un fenilo, naftilo o un heterociclo, cicloalquilo C3-7 sustituido con alquilo C1-6, fenilo, naftilo o heterociclo, o bien R10 y R11, considerados junto con el átomo de N al cual están unidos, forman un heterociclo, estando en cada caso dichos alquilo, cicloalquilo, fenilo, naftilo y heterociclo sustituidos opcionalmente con 1 a 3 átomos o grupos seleccionados de oxo, halogeno, CF3, CN, R12, OR12, NR12R13, COR12, CO2R12, S(O)pR12, S(O)pNR12R13, CONR12R13 y NR12COR13; R12 y R13 son, de manera independiente, H, alquilo C1-6 o alquilo C1-6 sustituido con cicloalquilo C3-7, o bien R12 y R13, cuando están unidos al mismo átomo de N, forman un heterociclo; Y es un enlace directo o un alquileno C1-4; n es 0, 1 o 2; p es 0, 1 o 2; con la salvedad de que, cuando Y sea metileno y R3 sea fenilo, R1 y R2 no sean simultáneamente metilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67805405P | 2005-05-04 | 2005-05-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054269A1 true AR054269A1 (es) | 2007-06-13 |
Family
ID=36698805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20060101788A AR054269A1 (es) | 2005-05-04 | 2006-05-03 | Derivados de 2-amido-6-amino-8-oxopurina |
Country Status (23)
Country | Link |
---|---|
US (1) | US7642350B2 (es) |
EP (1) | EP1888587A1 (es) |
JP (1) | JP2008540396A (es) |
KR (1) | KR20080006004A (es) |
CN (1) | CN101203519A (es) |
AR (1) | AR054269A1 (es) |
AU (1) | AU2006242920A1 (es) |
BR (1) | BRPI0611435A2 (es) |
CA (1) | CA2607780A1 (es) |
DO (1) | DOP2006000102A (es) |
EA (1) | EA200702235A1 (es) |
GT (1) | GT200600184A (es) |
IL (1) | IL187135A0 (es) |
MA (1) | MA29533B1 (es) |
MX (1) | MX2007013780A (es) |
NL (1) | NL1031741C2 (es) |
NO (1) | NO20076185L (es) |
PE (1) | PE20061439A1 (es) |
TN (1) | TNSN07411A1 (es) |
TW (1) | TW200716125A (es) |
UY (1) | UY29516A1 (es) |
WO (1) | WO2006117670A1 (es) |
ZA (1) | ZA200709591B (es) |
Families Citing this family (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US7754728B2 (en) * | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
JP4472693B2 (ja) | 2004-03-26 | 2010-06-02 | 大日本住友製薬株式会社 | 9置換−8−オキソアデニン化合物 |
US20090118263A1 (en) * | 2005-09-22 | 2009-05-07 | Dainippon Sumitomo Pharma Co., Ltd. | Novel Adenine Compound |
WO2008004948A1 (en) | 2006-07-05 | 2008-01-10 | Astrazeneca Ab | 8-oxoadenine derivatives acting as modulators of tlr7 |
ATE476966T1 (de) * | 2006-10-17 | 2010-08-15 | Bend Res Inc | Feste dispersion mit schwer wasserlöslichem wirkstoff |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
WO2008101867A1 (en) * | 2007-02-19 | 2008-08-28 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
ES2373616T3 (es) * | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | Compuestos de 8-oxo-adenina 9 sustituidos como moduladores del receptor de tipo toll (tlr7). |
ES2457316T3 (es) * | 2007-03-19 | 2014-04-25 | Astrazeneca Ab | Compuestos 8-oxo-adenina 9 sustituidos como moduladores del receptor similares a toll (TLR7) |
PE20081887A1 (es) * | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | Nuevo compuesto de adenina |
JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
US8568777B2 (en) * | 2007-03-30 | 2013-10-29 | Monosol Rx, Llc | Packaged film dosage unit containing a complexate |
DK2155743T3 (da) * | 2007-05-08 | 2012-11-05 | Astrazeneca Ab | Imidazoquinoliner med immunmodulerende egenskaber |
MX2009013832A (es) | 2007-06-29 | 2010-03-10 | Gilead Sciences Inc | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. |
PE20091156A1 (es) | 2007-12-17 | 2009-09-03 | Astrazeneca Ab | Sales de (3-{[[3-(6-amino-2-butoxi-8-oxo-7,8-dihidro-9h-purin-9-il)propil](3-morfolin-4-ilpropil)amino]metil}fenil)acetato de metilo |
US20110054168A1 (en) * | 2008-01-17 | 2011-03-03 | Ayumu Kurimoto | Method for preparing adenine compound |
US8865896B2 (en) | 2008-01-17 | 2014-10-21 | Astrazeneca Aktiebolag | Method for preparing adenine compound |
JP5519670B2 (ja) | 2008-08-11 | 2014-06-11 | グラクソスミスクライン エルエルシー | アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体 |
US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
KR101649881B1 (ko) | 2008-08-11 | 2016-08-30 | 글락소스미스클라인 엘엘씨 | 신규의 아데닌 유도체 |
EP2364314B1 (en) | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
NO2477987T3 (es) | 2009-09-14 | 2018-06-09 | ||
JP5694345B2 (ja) * | 2009-10-22 | 2015-04-01 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体の調節因子 |
JP2013512859A (ja) * | 2009-12-03 | 2013-04-18 | 大日本住友製薬株式会社 | トール様受容体(tlr)を介して作用するイミダゾキノリン |
WO2011079016A1 (en) * | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
WO2011098451A1 (en) | 2010-02-10 | 2011-08-18 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
CN103118682A (zh) * | 2010-04-30 | 2013-05-22 | 加利福尼亚大学校务委员会 | 合成tlr7激动剂的磷脂缀合物的用途 |
US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
JP5978225B2 (ja) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | 治療に有用なイミダゾ[4,5−c]キノリン−1−イル誘導体 |
DK2651943T3 (en) | 2010-12-17 | 2017-06-06 | Sumitomo Dainippon Pharma Co Ltd | purine derivatives |
EP2694484B1 (en) | 2011-04-08 | 2018-07-18 | Janssen Sciences Ireland UC | Pyrimidine derivatives for the treatment of viral infections |
EP2709989B8 (en) | 2011-05-18 | 2018-04-18 | Janssen Sciences Ireland UC | Quinazoline derivatives for the treatment of viral infections and further diseases |
PL2734186T3 (pl) | 2011-07-22 | 2019-01-31 | Glaxosmithkline Llc | Kompozycja |
BR112014011162A2 (pt) | 2011-11-09 | 2017-05-09 | Janssen R&D Ireland | derivados purínicos para o tratamento de infecções virais |
AU2013218072B2 (en) | 2012-02-08 | 2017-08-31 | Janssen Sciences Ireland Uc | Piperidino-pyrimidine derivatives for the treatment of viral infections |
EA035790B1 (ru) | 2012-07-13 | 2020-08-11 | Янссен Сайенсиз Айрлэнд Юси | Макроциклические пурины для лечения вирусных инфекций |
MX369417B (es) | 2012-08-10 | 2019-11-07 | Janssen Sciences Ireland Uc | Derivados de alquilpirimidina para el tratamiento de infecciones víricas y otras enfermedades. |
SG11201500787YA (en) | 2012-08-24 | 2015-03-30 | Glaxosmithkline Llc | Pyrazolopyrimidine compounds |
EP2712866A1 (en) | 2012-10-01 | 2014-04-02 | Centre National de la Recherche Scientifique (CNRS) | 1,2,4-triazine derivatives for the treatment of viral infections |
HUE037064T2 (hu) | 2012-10-10 | 2018-08-28 | Janssen Sciences Ireland Uc | Pirrolo[3,2-d]-pirimidin származékok vírusos fertõzések és egyéb betegségek kezelésére |
US9663474B2 (en) | 2012-11-16 | 2017-05-30 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino quinazoline derivatives for the treatment of viral infections |
ES2625023T3 (es) | 2012-11-20 | 2017-07-18 | Glaxosmithkline Llc | Compuestos novedosos |
JP6228223B2 (ja) | 2012-11-20 | 2017-11-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 新規化合物 |
US9550785B2 (en) | 2012-11-20 | 2017-01-24 | Glaxosmithkline Llc | Pyrrolopyrimidines as therapeutic agents for the treatment of diseases |
ES2733361T3 (es) | 2013-02-21 | 2019-11-28 | Janssen Sciences Ireland Unlimited Co | Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas |
HUE031908T2 (en) * | 2013-03-29 | 2017-08-28 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
CN105377833B (zh) | 2013-05-24 | 2018-11-06 | 爱尔兰詹森科学公司 | 用于治疗病毒感染和另外的疾病的吡啶酮衍生物 |
KR101482999B1 (ko) * | 2013-06-17 | 2015-01-14 | 순천향대학교 산학협력단 | 톨-유사 수용체(tlr)에 의해 유도되는 trif-의존성 신호전달 경로의 억제제로서의 (e)-1-(2-(2-니트로 비닐)페닐)피롤리딘(nvpp)을 유효성분으로 포함하는 항염증제 |
WO2014207082A1 (en) | 2013-06-27 | 2014-12-31 | Janssen R&D Ireland | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases |
KR102322425B1 (ko) | 2013-07-30 | 2021-11-05 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 바이러스 감염의 치료를 위한 티에노[3,2-d]피리미딘 유도체 |
NZ728072A (en) | 2014-07-11 | 2018-06-29 | Gilead Sciences Inc | Modulators of toll-like receptors for the treatment of hiv |
JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体モジュレーターの固体形態 |
CN107074860B (zh) | 2014-09-16 | 2022-07-15 | 吉利德科学公司 | 制备toll样受体调节剂的方法 |
KR20180003612A (ko) | 2015-05-08 | 2018-01-09 | 에프. 호프만-라 로슈 아게 | 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체 |
EP3567045B1 (en) | 2015-07-02 | 2022-01-12 | F. Hoffmann-La Roche AG | Benzoxazepin oxazolidinone compounds and methods of use |
WO2017188287A1 (ja) * | 2016-04-26 | 2017-11-02 | 大日本住友製薬株式会社 | 置換プリン誘導体 |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
BR112018072539A2 (pt) | 2016-05-05 | 2019-03-26 | Aquestive Therapeutics, Inc. | composições de epinefrina de administração aumentada |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
CN106008506B (zh) * | 2016-06-27 | 2018-02-13 | 山东大学 | 取代嘌呤类衍生物及其制备方法与应用 |
AU2017289418B2 (en) | 2016-07-01 | 2021-06-03 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
PT3504210T (pt) | 2016-08-29 | 2021-04-19 | H Hoffnabb La Roche Ag | Compostos de sulfonimidoílpurinona 7-substituídos para o tratamento e profilaxia de infeção por vírus |
KR102497701B1 (ko) | 2016-09-13 | 2023-02-09 | 에프. 호프만-라 로슈 아게 | Tlr7 작용제 및 hbv 캡시드 조립 억제제의 병용 치료 |
EP3519406B1 (en) | 2016-09-29 | 2022-02-23 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
WO2018133845A1 (zh) * | 2017-01-23 | 2018-07-26 | 上海长森药业有限公司 | 硫脲类、脲类化合物及其用途 |
JP2020524718A (ja) * | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドCuradev Pharma Limited | ヒトstingの複素環式小分子調節因子 |
GB2572526A (en) * | 2017-06-22 | 2019-10-09 | Curadev Pharma Ltd | Heterocyclic small molecule modulators of human STING |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
US10487084B2 (en) | 2017-08-16 | 2019-11-26 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor |
US10508115B2 (en) | 2017-08-16 | 2019-12-17 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor |
US10457681B2 (en) | 2017-08-16 | 2019-10-29 | Bristol_Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor |
US10494370B2 (en) | 2017-08-16 | 2019-12-03 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor |
JP7328977B2 (ja) | 2018-02-12 | 2023-08-17 | エフ. ホフマン-ラ ロシュ アーゲー | ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体 |
TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-二胺基喹唑啉衍生物及其醫學用途 |
WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
CA3140707A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
WO2021154667A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
US20230348468A1 (en) | 2020-01-27 | 2023-11-02 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
JP2023512205A (ja) | 2020-01-27 | 2023-03-24 | ブリストル-マイヤーズ スクイブ カンパニー | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 |
EP4097104A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
CN115279765A (zh) | 2020-01-27 | 2022-11-01 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
CN115151547A (zh) | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
CN115135655A (zh) | 2020-01-27 | 2022-09-30 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
CN115643805A (zh) | 2020-01-27 | 2023-01-24 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
EP4097105A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
US20230382886A1 (en) | 2020-10-21 | 2023-11-30 | Univerza V Ljubljani | Conjugated tlr7 and nod2 agonists |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
AU698419B2 (en) | 1996-07-03 | 1998-10-29 | Dainippon Sumitomo Pharma Co., Ltd. | A novel purine derivative |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
NZ504800A (en) | 1997-11-28 | 2001-10-26 | Sumitomo Pharma | 6-Amino-9-benzyl-8-hydroxy-purine derivatives and interferon inducers, antiviral agents, anticancer agents and therapeutic agents for immunologic diseases thereof |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
CN101928288B (zh) * | 2000-11-02 | 2013-09-11 | 斯隆-凯特林癌症研究所 | 结合hsp90的小分子组合物 |
JP4331944B2 (ja) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
US7754728B2 (en) * | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
US20040191833A1 (en) | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Selective activation of cellular activities mediated through a common toll-like receptor |
EA200600540A1 (ru) | 2003-09-05 | 2006-08-25 | Анадис Фармасьютикалз, Инк. | Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с |
TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
ATE476966T1 (de) * | 2006-10-17 | 2010-08-15 | Bend Res Inc | Feste dispersion mit schwer wasserlöslichem wirkstoff |
MX2009013832A (es) * | 2007-06-29 | 2010-03-10 | Gilead Sciences Inc | Derivados de purina y su uso como moduladores del receptor 7 similar a un puente. |
-
2006
- 2006-04-24 EP EP06727586A patent/EP1888587A1/en not_active Withdrawn
- 2006-04-24 AU AU2006242920A patent/AU2006242920A1/en not_active Abandoned
- 2006-04-24 CN CNA2006800222871A patent/CN101203519A/zh active Pending
- 2006-04-24 WO PCT/IB2006/001181 patent/WO2006117670A1/en active Application Filing
- 2006-04-24 MX MX2007013780A patent/MX2007013780A/es not_active Application Discontinuation
- 2006-04-24 EA EA200702235A patent/EA200702235A1/ru unknown
- 2006-04-24 KR KR1020077028186A patent/KR20080006004A/ko not_active Application Discontinuation
- 2006-04-24 JP JP2008509532A patent/JP2008540396A/ja not_active Withdrawn
- 2006-04-24 BR BRPI0611435-0A patent/BRPI0611435A2/pt not_active IP Right Cessation
- 2006-04-24 CA CA002607780A patent/CA2607780A1/en not_active Abandoned
- 2006-05-02 PE PE2006000461A patent/PE20061439A1/es not_active Application Discontinuation
- 2006-05-03 NL NL1031741A patent/NL1031741C2/nl not_active IP Right Cessation
- 2006-05-03 DO DO2006000102A patent/DOP2006000102A/es unknown
- 2006-05-03 AR AR20060101788A patent/AR054269A1/es unknown
- 2006-05-03 TW TW095115722A patent/TW200716125A/zh unknown
- 2006-05-03 UY UY29516A patent/UY29516A1/es not_active Application Discontinuation
- 2006-05-03 US US11/417,982 patent/US7642350B2/en not_active Expired - Fee Related
- 2006-05-03 GT GT200600184A patent/GT200600184A/es unknown
-
2007
- 2007-11-02 TN TNP2007000411A patent/TNSN07411A1/fr unknown
- 2007-11-04 IL IL187135A patent/IL187135A0/en unknown
- 2007-11-07 ZA ZA200709591A patent/ZA200709591B/xx unknown
- 2007-11-30 NO NO20076185A patent/NO20076185L/no not_active Application Discontinuation
- 2007-12-04 MA MA30452A patent/MA29533B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
KR20080006004A (ko) | 2008-01-15 |
US7642350B2 (en) | 2010-01-05 |
PE20061439A1 (es) | 2007-02-03 |
IL187135A0 (en) | 2008-02-09 |
MX2007013780A (es) | 2008-02-05 |
NO20076185L (no) | 2008-02-01 |
CA2607780A1 (en) | 2006-11-09 |
DOP2006000102A (es) | 2006-11-15 |
BRPI0611435A2 (pt) | 2010-09-08 |
NL1031741C2 (nl) | 2007-07-10 |
UY29516A1 (es) | 2006-11-30 |
TNSN07411A1 (fr) | 2009-03-17 |
TW200716125A (en) | 2007-05-01 |
NL1031741A1 (nl) | 2006-11-07 |
AU2006242920A1 (en) | 2006-11-09 |
CN101203519A (zh) | 2008-06-18 |
GT200600184A (es) | 2006-11-28 |
JP2008540396A (ja) | 2008-11-20 |
US20060264448A1 (en) | 2006-11-23 |
MA29533B1 (fr) | 2008-06-02 |
ZA200709591B (en) | 2010-01-27 |
WO2006117670A1 (en) | 2006-11-09 |
EA200702235A1 (ru) | 2008-04-28 |
EP1888587A1 (en) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054269A1 (es) | Derivados de 2-amido-6-amino-8-oxopurina | |
AR049388A1 (es) | Heterociclos como inhibidores de aldosterona sintasa | |
ES2525007T3 (es) | Nucleósidos ciclopropílicos de uracilo | |
AR127309A2 (es) | Derivados de piridazinona | |
AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
AR086357A1 (es) | Derivados de indazol sustituidos activos como inhibidores de quinasas | |
AR049125A1 (es) | Heterociclos biciclicos nitrogenados inhibidores de la aromatasa. | |
TN2016000503A1 (en) | Pyrazolopyridines and pyrazolopyrimidines | |
AR065276A1 (es) | Herbicidas de n-oxidos de piridina sustituidos | |
JP2014503516A5 (es) | ||
PE20130012A1 (es) | Derivados de pirazol como inhibidores de jak | |
JP2007511527A5 (es) | ||
AR065280A1 (es) | Agentes antiparasitarios | |
AR084353A1 (es) | Enonas triciclicas de pirazolilo y pirimidinilo utiles como agentes antiinflamatorios y/o antioxidantes y composiciones farmaceuticas que las contienen | |
AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
AR081848A1 (es) | Inhibidores de la proteina ns5a del vhc | |
AR078151A1 (es) | Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas. | |
JP2014518882A5 (es) | ||
AR051461A1 (es) | Compuesto de pirazolo[1,5-a]pirimidin-7-il-amina forma poliformica 1 de [3-(4-metoxi-2-metil-fenil)-2,5-dimetil-pirazolo[1,5-a]pirimidin-7-il]-[(s)-1-(3-metil-[1,2,4]oxadiazol-5-il)-propil]-amina, composicion farmaceutica que lo comprende y su uso para prepararla | |
JP2010513523A5 (es) | ||
ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
CY1114908T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
AR062731A1 (es) | Derivados de quinazolinona e isoquinolinona, composiciones farmaceuticas que los contienen, y su uso para tratar o prevenir trastornos relacionados con el estres o la depresion. | |
AR074089A1 (es) | Antagonistas de cicloalcano (b) azaindol de los receptores de la postaglandina d2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |